Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis

Trial Profile

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparin
  • Indications Venous thrombosis
  • Focus Adverse reactions
  • Acronyms SECRET
  • Most Recent Events

    • 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 31 Oct 2018.
    • 01 Aug 2018 Planned number of patients changed from 384 to 380.
    • 01 Aug 2018 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top